Nuformix has today filed a provisional patent application covering numerous novel solid forms of its NX006 product.
NX006 is a leading muscle relaxant with annual sales exceeding £340m in 2009. The novel solid forms of NX006, re-engineered by Nuformix, offer new options in terms of achieving increased bioavailability of this highly insoluble drug.
The patent application was conceived together with Jeffrey A. Lindeman who is an esteemed Intellectual Property consultant and world renowned thought leader in the field of legal issues relating to pharmaceutical solid form at the firm J. A. Lindeman LLC.